Managing Myeloma: Examining the Evidence in Frontline Therapy
Release Date: January 30, 2023
Expiration Date: January 30, 2024
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In recent years, important new advances have been reported in the frontline treatment of newly diagnosed multiple myeloma (NDMM) patients. Despite this progress, however, significant challenges remain. In this activity, two myeloma experts will discuss the most recent information and evidence regarding frontline therapy including selecting regimens based on individual patient disease factors, treatment regimens for transplant-ineligible and transplant-eligible patients, and key practice considerations for NDMM.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Outline practical strategies for implementing new and evolving standards of care into treatment of patients with NDMM
- Summarize clinical data supporting the use of triplet and quadruplet regimens in NDMM patients
- Correlate patient and/or disease characteristics with appropriate triplet or quadruplet regimens in NDMM (transplant eligible and ineligible)
- Identify factors to be considered when developing an optimized treatment sequencing strategy for an individual NDMM patient
Managing Myeloma: Examining the Evidence in Frontline Therapy – Amrita Krishnan, MD, FACP and Saad Z. Usmani, MD, MBA, FACP
Instructions for Participation and Credit
This activity is eligible for credit through January 30, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope
Los Angeles, California
Dr. Amrita Krishnan is the Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Los Angeles, California. She has been instrumental in initiating City of Hope’s involvement in developing and evaluating several new drugs for myeloma, leading to FDA approval of four of these agents. Dr. Krishnan is currently on the steering committee for the Multiple Myeloma Research Foundation and has led her own investigator-initiated Phase I/II trials through the MMRF. In addition, she is past chair of the myeloma committee of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a national cooperative group of leading transplant centers. Dr. Krishnan was the principal investigator (PI) for two of the largest myeloma transplant trials conducted through the BMT CTN, one investigating the role of allogeneic transplantation in myeloma and one studying novel agents post-transplant for myeloma.
Dr. Krishnan’s research in myeloma includes serving as past chair of the plasma cell/lymphoma committee of the American Society of Clinical Oncology (ASCO) and former co-chair of the CIBMTR plasma cell committee, as well as the North American representative to the International Myeloma Society. Her research interests are focused on developing novel therapies and imaging modalities for myeloma. She has served as the PI of a published trial using daratumumab-based imaging in myeloma and also has experience in investigating radiolabeled antibodies for hematologic malignancies.
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He now serves as the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College, New York City.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has authored/co-authored more than 190 peer-reviewed research manuscripts and 230 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-004-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-004-161
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Amrita Krishnan has relevant financial relationships related to consulting activities from AbbVie Inc., Adaptive Biotechnologies, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., and Sanofi. She is on the speakers’ bureau for Bristol Myers Squibb Company, Sutro Biopharma, and Takeda Oncology.
Dr. Saad Usmani has relevant financial relationships related to advisory activities and consulting from AbbVie, Inc., Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation - A Bristol Myers Squibb Company, Edo Pharma, Genentech, Inc., Gilead, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Oncopeptides, AB, Sanofi, Seattle Genetics, Inc., SecuraBio, Skyline Diagnostics B.V, Takeda Oncology, and TeneoBio.
He has received research grant(s) from Amgen Inc., Array BioPharma, Bristol Myers Squibb Company, Celgene Corporation - A Bristol Myers Squibb Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pharmacyclics, Inc., Sanofi, Seattle Genetics, Skyline Diagnostics B.V, and Takeda Oncology.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.